Research Articles | Page 19 | Aplastic Anemia & MDS International Foundation Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients Jan 2016 Immunobiology paroxysmal nocturnal hemoglobinuria (PNH)
Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria Mar 2014 J Hematol Oncol paroxysmal nocturnal hemoglobinuria (PNH)
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria Jul 2020 Blood aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria May 2020 Blood aplastic anemia, myelodysplastic syndromes (MDS), paroxysmal nocturnal hemoglobinuria (PNH)
Second allogeneic hematopoietic stem cell transplantation in children with severe aplastic anemia Jun 2015 Bone Marrow Transplant aplastic anemia
Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes. Jan 2017 Am Soc Clin Oncol Educ Book myelodysplastic syndromes (MDS)
Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes Jun 2016 Am Soc Clin Oncol Educ Book myelodysplastic syndromes (MDS)
Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes Jan 2017 Ther Adv Hematol myelodysplastic syndromes (MDS)
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial Aug 2020 Lancet Hematology acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy Jun 2017 Br J Haematol myelodysplastic syndromes (MDS)
Share with addtoany.com.